Jeff Yass’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-28,582
Closed -$876K – 14704
2026
Q2
$993K Sell
28,582
-2,316
-7% -$68.4K ﹤0.01% 8222
2026
Q1
$713K Sell
30,898
-211,930
-87% -$4.79M ﹤0.01% 8773
2025
Q4
$4.89M Buy
+242,828
New +$5.05M ﹤0.01% 4055
2025
Q3
– Sell
-29,611
Closed -$582K – 14106
2025
Q2
$645K Sell
29,611
-7,180
-20% -$149K ﹤0.01% 8579
2025
Q1
$680K Buy
36,791
+18,955
+106% +$464K ﹤0.01% 8214
2024
Q4
$475K Buy
+17,836
New +$512K ﹤0.01% 8785

Other funds holding AVBP

Jeff Yass's AVBP Position: Q3 2026 in Review

Jeff Yass sold out of ArriVent BioPharma (AVBP) in Q3 2026, closing a stake of 28,582 shares — an estimated $876K sold.

Jeff Yass first reported a position in AVBP in Q4 2024 and held it in 6 quarters. The position peaked at $4.89M in Q4 2025. 153 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Jeff Yass reported no remaining ArriVent BioPharma position as of Q3 2026 after selling out during the quarter.
  • Jeff Yass sold 28,582 ArriVent BioPharma shares in Q3 2026, an estimated $876K.
  • Jeff Yass first reported a position in ArriVent BioPharma in Q4 2024 and held it in 6 quarters.
  • Jeff Yass's ArriVent BioPharma position peaked at $4.89M in Q4 2025.
  • 153 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.